AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference, a virtual conference held March 9-10, 2021.
| NEW YORK, March 1, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference, a virtual conference held March 9-10, 2021. The Company will showcase an updated Investor Presentation and discuss some of its new technology. Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will present for the Company.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (https://hcwevents.com/globalconference/) to register for the conference. About H.C. Wainwright H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. About AIkido Pharma Inc. Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Contact: Investor Relations: Hayden IR AIkido Pharma Inc.: Phone: 212-745-1373
SOURCE AIkido Pharma Inc. | ||
Company Codes: NASDAQ-NMS:AIKI |
View original content to download multimedia:
